1. Diagnosis and management of aspergillosis in the Netherlands: a national survey
- Author
-
Martha T. van der Beek, Caspar J. Hodiamont, Sabine C. de Greeff, Els de Brauwer, Ed J. Kuijper, Bart J. A. Rijnders, Eveline Roelofsen, Cees M. Verduin, Paul E. Verweij, Jacques F. Meis, Wouter Rozemeijer, E.M. Terveer, Anouk E. Muller, Maurice J.H.M. Wolfhagen, Mathijs Tersmette, Pieter Jan Haas, Tjalling Leenstra, Karin van Dijk, Willem J. G. Melchers, Astrid M. L. Oude Lashof, Jan P. Arends, Pieter P. A. Lestrade, Medical Microbiology and Infection Prevention, Graduate School, Infectious diseases, Medical Microbiology & Infectious Diseases, Medische Microbiologie, MUMC+: DA MMI Staf (9), RS: FHML non-thematic output, and Interne Geneeskunde
- Subjects
MECHANISM ,0301 basic medicine ,medicine.medical_specialty ,Antifungal Agents ,TRIAZOLE RESISTANCE ,030106 microbiology ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,Azole resistance ,Dermatology ,FREQUENCY ,Aspergillosis ,Aspergillus fumigatus ,03 medical and health sciences ,azole resistance ,Drug Resistance, Fungal ,Amphotericin B ,Surveys and Questionnaires ,Internal medicine ,SURVEILLANCE ,medicine ,Humans ,University medical ,TR34/L98H MUTATIONS ,Intensive care medicine ,Netherlands ,Voriconazole ,ENVIRONMENT ,Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17] ,FUMIGATUS ,treatment ,biology ,business.industry ,STRAINS ,Hospital level ,General Medicine ,biology.organism_classification ,medicine.disease ,PREVALENCE ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Infectious Diseases ,Liposomal amphotericin ,business ,medicine.drug - Abstract
Contains fulltext : 172306.pdf (Publisher’s version ) (Closed access) A survey of diagnosis and treatment of invasive aspergillosis was conducted in eight University Medical Centers (UMCs) and eight non-academic teaching hospitals in the Netherlands. Against a background of emerging azole resistance in Aspergillus fumigatus routine resistance screening of clinical isolates was performed primarily in the UMCs. Azole resistance rates at the hospital level varied between 5% and 10%, although rates up to 30% were reported in high-risk wards. Voriconazole remained first choice for invasive aspergillosis in 13 out of 16 hospitals. In documented azole resistance 14 out of 16 centres treated patients with liposomal amphotericin B.
- Published
- 2016
- Full Text
- View/download PDF